Filing Details
FATE THERAPEUTICS INC (NASDAQ:FATE) filed a Form 8-K with the Securities and Exchange Commission on August 13, 2026, disclosing a material event.
8k filedNASDAQ:FATE
FATE THERAPEUTICS INC (FATE) Reports Material Event to SEC
FATE THERAPEUTICS INC (NASDAQ:FATE) filed a Form 8-K with the Securities and Exchange Commission on August 13, 2026, disclosing a material event.
At publication ·
What changed
FATE THERAPEUTICS INC (NASDAQ:FATE) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- FATE Therapeutics filed a Form 8-K with the SEC on August 13, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this filing notice.
- The company's stock was trading at $2.52 per share with a market capitalization of $128.0 million at the time of the filing.
- Material events reported on Form 8-K can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance, but the actual event details are not specified in this document.
Market Context
FATE THERAPEUTICS INC's stock currently trades at $2.52 with a market capitalization of $128.0M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for FATE THERAPEUTICS INC's stock.
All SEC filings for FATE THERAPEUTICS INC are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View FATE Stock Page
Frequently Asked Questions
Where can I read FATE's SEC filings?
Browse all filings on our FATE SEC filings page.
What types of SEC filings does FATE THERAPEUTICS INC file?
Public companies like FATE THERAPEUTICS INC file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.